Miscellaneous Indications in Bone Scintigraphy: Metabolic Bone Diseases and Malignant Bone Tumors

Seminars in Nuclear Medicine

Volumn 40, Issue 1, 2010, Pages 52-61

  Cook, Gary J R ^a   Gnanasegaran, Gopinath ^b   Chua, Sue ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

BONE SCINTISCANNING; BONE TUMOR; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; HYPERPARATHYROIDISM; MALIGNANT NEOPLASTIC DISEASE; METABOLIC BONE DISEASE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSITRON EMISSION TOMOGRAPHY; RENAL OSTEODYSTROPHY; REVIEW; SURGICAL TECHNIQUE; TREATMENT RESPONSE; VERTEBRA FRACTURE;

BONE AND BONES; BONE DISEASES, METABOLIC; BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; RADIONUCLIDE IMAGING;

EID: 70549111622     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.08.002     Document Type: Review

References (66)

1. Hughes S., Khan R., Davies R., et al. The uptake by the canine tibia of the bone-scanning agent 99mTc-MDP before and after an osteotomy. J Bone Joint Surg Br 60-B (1978) 579-582
2. 99mTc-methylene diphosphonate. Semin Nucl Med 31 (2001) 28-49
3. Fogelman I., Bessent R.G., Turner J.G., et al. The use of whole-body retention of Tc99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 19 (1978) 270-275
4. Fogelman I., Bessent R.G., Cohen H.N., et al. Skeletal uptake of diphosphonate. Method for prediction of postmenopausal osteoporosis. Lancet 2 (1980) 667-670
5. Front D., Israel O., Jerushalmi J., et al. Quantitative bone scintigraphy using SPECT. J Nucl Med 30 (1989) 240-245
6. Israel O., Lubushitzky R., Frenkel A., et al. Bone turnover in cortical and trabecular bone in normal women and in women with osteoporosis. J Nucl Med 35 (1994) 1155-1158
7. Cook G.J.R., Lodge M.A., Blake G.M., et al. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride PET. J Bone Miner Res 15 (2000) 763-769
8. Frost M.L., Blake G.M., Park-Holohan S.J., et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med 49 (2008) 700-707
9. Frost M.L., Cook G.J., Blake G.M., et al. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover. J Clin Densitom 10 (2007) 46-54
10. Frost M.L., Fogelman I., Blake G.M., et al. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res 19 (2004) 1797-1804
11. Schiepers C., Nuyts J., Bormans G., et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 38 (1997) 1970-1976
12. Frost M.L., Cook G.J., Blake G.M., et al. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res 18 (2003) 2215-2222
13. Spitz J., Lauer I., Tittel K., et al. Scintimetric evaluation of remodeling after bone fractures in man. J Nucl Med 34 (1993) 1403-1409
14. Eastell R., Cedel S.L., Wahner H.W., et al. Classification of vertebral fractures. J Bone Miner Res 6 (1991) 207-215
15. Ryan P.J., and Fogelman I. Osteoporotic vertebral fractures: Diagnosis with radiography and bone scintigraphy. Radiology 190 (1994) 669-672
16. Cook G.J.R., Hannaford E., Lee M., et al. The value of bone scintigraphy in the evaluation of osteoporotic patients with back pain. Scand J Rheumatol 31 (2002) 245-248
17. Ryan P.J., Evans P.A., Gibson T., et al. Osteoporosis and chronic back pain: A study with single photon emission computed bone scintigraphy. J Bone Miner Res 7 (1992) 1455-1459
18. Fogelman I., and Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget's disease. Eur J Nucl Med 5 (1980) 417-421
19. Rotés-Sala D., Monfort J., Solano A., et al. The clover and heart signs in vertebral scintigraphic images are highly specific of Paget's disease of bone. Bone 34 (2004) 605-608
20. Estrada W.N., and Kim C.K. Paget's disease in a patient with breast cancer. J Nucl Med 34 (1993) 1214-1216
21. Ryan P.J., Gibson T., and Fogelman I. Bone scintigraphy following pamidronate therapy for Paget's disease of bone. J Nucl Med 33 (1992) 1589-1593
22. Patel S., Pearson D., and Hosking D.J. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Arthritis Rheum 38 (1995) 1506-1512
23. Ryan W.G., Fordham E.W., and Ali A. Treated Paget's disease of bone mimicking metastatic cancer. Clin Nucl Med 20 (1995) 69
24. Smith M.L., Fogelman I., Ralston S., et al. Correlation of skeletal uptake of 99mTc-diphosphonate and alkaline phosphatase before and after oral diphosphonate therapy in Paget's disease. Metab Bone Dis Relat Res 5 (1984) 167-170
25. Pons F., Alvarez L., Peris P., et al. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity. Nucl Med Commun 20 (1999) 525-528
26. Hadjipavlou A., Lisbona R., Garbuz D., et al. Whole body retention of Tc99m phosphate in Paget's disease of bone. Clin Nucl Med 16 (1991) 435-438
27. Vellenga C.J., Pauwels E.K., Bijvoet O.L., et al. Quantitative bone scintigraphy in Paget's disease treated with APD. Br J Radiol 58 (1985) 1165-1172
28. Vellenga C.J., Pauwels E.K., and Bijvoet O.L. Comparison between visual assessment and quantitative measurement of radioactivity on the bone scintigram in Paget's disease of bone. Eur J Nucl Med 9 (1984) 533-537
29. Fogelman I., Bessent R.G., and Gordon D. A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease. Eur J Nucl Med 6 (1981) 93-97
30. Griffith K., Pearson D., Parker C., et al. The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease. Nucl Med Commun 22 (2001) 1069-1075
31. Cook G.J., Blake G.M., Marsden P.K., et al. Quantification of skeletal kinetic indices in Paget's disease using dynamic18F-fluoride positron emission tomography. J Bone Miner Res 17 (2002) 854-859
32. Installé J., Nzeusseu A., Bol A., et al. (18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med 46 (2005) 1650-1658
33. Cook G.J.R., Maisey M.N., and Fogelman I. Paget's disease of bone: Appearances with 18-FDG PET. J Nucl Med 38 (1997) 1495-1497
34. Fogelman I., and Carr D. A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease. Clin Radiol 31 (1980) 321-326
35. Messa C., Goodman W.G., Hoh C.K., et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry. J Clin Endocrinol Metab 77 (1993) 949-955
36. Fogelman I., McKillop J.H., Bessent R.G., et al. The role of bone scanning in osteomalacia. J Nucl Med 19 (1978) 245-248
37. Fogelman I., McKillop J.H., Greig W.R., et al. Pseudofractures of the ribs detected by bone scanning. J Nucl Med 18 (1977) 1236-1237
38. McLean R.G., and Murray I.P. Scintigraphic patterns in certain primary bone tumours. Clin Radiol 35 (1984) 379-383
39. Simon M.A., and Kirchner P.T. Scintigraphic evaluation of primary bone tumours. J Bone Joint Surg 62 (1980) 758-764
40. McKillop J.H., Etcubanas E., and Goris M.L. The indications for and the limitations of bone scintigraphy in osteogenic sarcoma. Cancer 48 (1981) 1133-1138
41. Goldmann A.B., Becker M.H., Braunstein P., et al. Bone scanning-Osteogenic sarcoma. Correlation with surgical pathology. Radiology 124 (1975) 83-90
42. Papanicolou N., Kozakewich H., Treves S., et al. Comparison of the extent of osteosarcoma between surgical pathology and skeletal scintigraphy. J Nucl Med 23 (1982) 7
43. Chew F.S., and Hudson T.M. Radionuclide bone scanning of osteosarcoma: Falsely extended uptake patterns. AJR Am J Roentgenol 139 (1982) 49-54
44. Ghaed N., Thrall J.H., Pinsky S.M., et al. Detection of extraosseous metastases from osteosarcoma with 99mTc-polyphosphate bone scanning. Radiology 112 (1974) 3373-3375
45. Ozcan Z., Burak Z., Kumanlioglu K., et al. Assessment of chemotherapy-induced changes in bone sarcomas: Clinical experience with 99mTc-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun 20 (1999) 41-48
46. Knop J., Delling G., Heise U., et al. Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99mTc-methylene diphosphonate parametric imagingwith surgical histopathology. Skeletal Radiol 9 (1990) 165-172
47. Sommer H.J., Knop J., Heise U., et al. Histomorphometric changes of osteosarcoma after chemotherapy. Correlation with 99mTc methylene diphosphonate functional imaging. Cancer 59 (1987) 252-258
48. Erlemann R., Sciuk J., Bosse A., et al. Response of osteosarcoma and Ewing's sarcoma to preoperative chemotherapy: Assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 175 (1990) 791-796
49. Aoki J., Watanabe H., Shinozaki T., et al. FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions. Radiology 219 (2001) 774-777
50. Dimitrakopoulou-Strauss A., Strauss L.G., et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 43 (2002) 510-518
51. 18FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol 38 (2009) 451-458
52. Strobel K., Exner U.E., Stumpe K.D., et al. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 35 (2008) 2000-2008
53. Völker T., Denecke T., Steffen I., et al. Positron emission tomography for staging of pediatric sarcoma patients: Results of a prospective multicenter trial. J Clin Oncol 25 (2007) 5435-5441
54. Kleis M., Daldrup-Link H., Matthay K., et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 36 (2009) 23-36
55. Kneisl J.S., Patt J.C., Johnson J.C., et al. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas?. Clin Orthop Relat Res 450 (2006) 101-104
56. Franzius C., Sciuk J., Daldrup-Link H.E., et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: Comparison with bone scintigraphy. Eur J Nucl Med 27 (2000) 1305-1311
57. Györke T., Zajic T., Lange A., et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 27 (2006) 17-24
58. Franzius C., Daldrup-Link H.E., Sciuk J., et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol 12 (2001) 479-486
59. Schulte M., Brecht-Krauss D., Werner M., et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40 (1999) 1637-1643
60. 18F-FDG-PET scans. Clin Positron Imaging 3 (2000) 79-83
61. Hawkins D.S., Schuetze S.M., Butrynski J.E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23 (2005) 8828-8834
62. Hawkins D.S., Rajendran J.G., Conrad E.U., et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 94 (2002) 3277-3284
63. 18FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 25 (2000) 874-881
64. Jones D.N., McCowage G.B., Sostman H.D., et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37 (1996) 1438-1444
65. Franzius C., Bielack S., Flege S., et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 43 (2002) 1012-1017
66. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 50 (2009) 340-347